ArticleSarcoma2011
Symptom burden, survival and palliative care in advanced soft tissue sarcoma.
Article in Sarcoma, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The Patient Experience with Soft Tissue Sarcoma: A Systematic Review of the Literature.The patient · 2017Pooled it
- Health-related quality of life and pain with selinexor in patients with advanced dedifferentiated liposarcoma.Future oncology (London, England) · 2021Trial
- Trial
- Trial
- Trial
- An analysis of palliative care in adolescents and young adults with soft tissue and bone sarcomas.Palliative care and social practice · 2026Article
- Patient-Reported Outcome Measurement and Reporting for Patients with Soft Tissue Tumors: A Scoping Literature Review.Cancers · 2025Review
- Palliative care outpatient interventions to limit aggressive care at end-of-life for patients with advanced soft tissue sarcomas.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Article
- Patient-physician agreement on function and pain is associated with long-term outcomes in sarcoma: findings from a longitudinal study.Journal of cancer survivorship : research and practice · 2025Article
- Article
- Priorities and preferences of advanced soft tissue sarcoma patients starting palliative chemotherapy: baseline results from the HOLISTIC study.ESMO open · 2021Article
- Adapting Management of Sarcomas in COVID-19: An Evidence-Based Review.Indian journal of orthopaedics · 2021Review
- Impact of a specialised palliative care intervention in patients with advanced soft tissue sarcoma - a single-centre retrospective analysis.BMC palliative care · 2021Article
- Article
- Article
- Article
- Retrospective quality of life study in patients with retroperitoneal sarcoma in an Asian population.Health and quality of life outcomes · 2020Article
- Health-related quality Of LifeBMJ open · 2020Article
- Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction. The symptom burden and role of palliative care (PC) in patients with advanced soft tissue sarcoma (STS) are not well defined. Methods. This study retrospectively reviewed both symptoms and PC involvement in patients known to an STS referral centre who died in one calendar year. Results. 81 patients met inclusion criteria of which 27% had locally advanced disease and 73% metastases at initial referral. The median number of symptoms was slowly progressive ranging from 2 (range 0-5) before first-line chemotherapy (n = 50) to 3 (range 1-6) at the time of best supportive care (BSC) decision (n = 48). Pain and dyspnoea were the commonest symptoms. Median overall survival from BSC decision was 3.4 weeks. 88% had PC involvement (either hospital, community, or both) with median time from first PC referral to death of 16 (range 0-110) weeks. Conclusions. Patients with metastatic STS have a significant symptom burden which justifies early PC referral. Pain, including neuropathic pain, is a significant problem. Dyspnoea is common, progressive and appears to be undertreated. Time from BSC decision to death is short, and prospective studies are required to determine whether this is due to overtreatment or very rapid terminal disease progression.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.